Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    North America Monoclonal Antibodies Market Forecast 2028 By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By Type (Fully Human, Humanized, Chimeric), By End-use (Hospitals, Specialty Centers), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: April 2022   |   Report ID: GR1896   |   Delivery: PDF  Request Free Sample

    North America Monoclonal Antibodies Market size crossed USD 87 billion in 2021 and is poised to expand at a CAGR of 12.8% between 2022 and 2028.

    Monoclonal antibodies also referred as MoAbs or mAbs, are identical immunoglobulins developed from a single B-cell clone. mAbs identify unique epitopes on a single antigen. Monoclonal antibodies have been widely accepted and approved for treatment of various life-threatening conditions owing to its specificity.  

    North America Monoclonal Antibodies Market

    Get more details on this report - Request Free Sample PDF

    Extensive product pipeline with potential effective therapies catering to diverse range of diseases is anticipated to propel the market growth. Regulatory approvals for innovative mAb products will positively influence the industry revenue. Further, growing usage of advanced genetic technologies will offer faster discovery and product development. Moreover, extensive R&D activities by the several organizations will favor new product launches in the region. Further, high prevalence of chronic diseases including cancer and infections across the region will create need for product innovation.

    Increase in number of approved monoclonal antibodies for cancer treatment has offered revenue growth opportunities to the market. Additionally, technological advancements in product development technologies have resulted into expanding applications of monoclonal antibodies as immunotherapeutic. Thus, increasing product adoption to minimize disease-associated mortality rate will excel the industry growth. Further, government initiatives, high healthcare expenditure will stimulate the market growth.

    The COVID-19 pandemic has positively impacted on North America monoclonal antibodies market growth. High need for effective therapeutics to combat high incidence rate and High mortality risk associated with the COVID-19 infection has driven market growth potential. Moreover, several organizations involved in development of highly effective therapies for COVID-19 treatment has propelled industry demand. Furthermore, government fundings for R&D activities as well as favourable regulatory scenario have fuelled overall market expansion during pandemic.

     North America Market, By Type

    North America Monoclonal Antibodies Market, By Type

    Get more details on this report - Request Free Sample PDF

    The fully human monoclonal antibodies segment held over 51% North America monoclonal antibodies market share in 2021, due to rapid surge in product developments for fully human mAb products. Further, technological proliferation in biological industry will positively influence the market revenue. Further, large availability of advanced fully human mAbs with wide applications in immunology will drive the market size.

     North America Monoclonal Antibodies Market, By Application

    The autoimmune diseases segment accounted for USD 27 billion revenue in 2021, owing to growing patient pool related to autoimmune diseases in the region. For instance, according to the Autoimmune Registry Inc (ARI), 15 to 30 million individuals were suffering from autoimmune diseases in the year 2021. Growing adoption of novel mAb therapeutics in treatment of several autoimmune disorders will offer substantial growth opportunities to the segment.

     North America Market, By End-use

    The hospitals segment will observe around 13.2% growth rate during the forecast timeline. Expanding accessibility to sophisticated healthcare infrastructure along with enhanced availability of innovative medicines in hospitals will spur the segment revenue share. In addition, growing hospital admissions and high chronic disease burden in the region will accelerate the market value.

     North America Market, By Country

    U.S. monoclonal antibodies market size exceeded USD 82 billion in 2021, credited to high prevalence rate of several chronic diseases in the country. Also, several mAbs candidates are being rapidly approved by the U.S. FDA.

    Further, emergence of COVID-19 virus has boosted new product development and approvals. For instance, the U.S. FDA has announced an emergency use authorization for the sotrovimab, an investigational monoclonal antibody therapy to treat COVID-19 patients with mild-to-moderate infections.

     Competitive Industry Landscape

    Major players operating in the North America monoclonal antibodies market include F. Hoffmann-La Roche, AbbVie Inc., Bristol Myers Squibb, Johnson & Johnson, Amgen, Regeneron, and Novartis AG.

    These companies are undertaking numerous growth strategies such as partnerships, collaborations, acquisitions, and product launches to gain competitive edge over others. For instance, in June 2021, Janssen, a subsidiary firm of Johnson & Johnson, received product grant as ‘Breakthrough Therapy Designation’ by the U.S. FDA for teclistamab used in the treatment of relapsed or refractory multiple myeloma. This will further strengthen its current offerings in the market.

    Frequently Asked Question(FAQ) :

    How big is North America monoclonal antibodies market?
    The industry size for monoclonal antibodies in North America was surpassed USD 87 billion in 2021 and is anticipated to register 12.8% CAGR between 2022 and 2028.
    How will North America fully human monoclonal antibodies industry share grow?
    The fully human segment held more than 51% of North America industry share in 2021 due to a notable increase in mAb product developments.
    What makes the U.S. an attractive market for monoclonal antibodies?
    The market value for monoclonal antibodies in U.S. was crossed USD 82 billion in 2021 due to the rising occurrence of severe diseases in the country and the high approval rate of mAb candidates.
    Which organizations are operating in North America monoclonal antibodies landscape?
    Bristol Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche, AbbVie Inc., Novartis AG, Regeneron, and Amgen, among several others, are the major players in this industry.

    Get this research report on North America Monoclonal Antibodies Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team


     [email protected]